Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study

Published:2024-04-26 Issue:5 Volume:11 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Ait-Khaled Mounir¹,Oyee James²,Ooi Adrian Yit Reen³,Wynne Brian⁴,Maldonado Andres⁵,Jones Bryn¹,Wang Tao⁶

Affiliation:

1. ViiV Healthcare , Brentford , United Kingdom

2. GSK , Brentford , United Kingdom

3. ViiV Healthcare , Singapore

4. ViiV Healthcare , Durham, North Carolina , USA

5. ViiV Healthcare , Wavre , Belgium

6. GSK , Shanghai , China

Abstract

Abstract TANGO results have established the durable efficacy of dolutegravir/lamivudine in virologically suppressed individuals who switched from 3- or 4-drug tenofovir alafenamide (TAF)–based regimens. In this post hoc subgroup analysis, 144-week efficacy and tolerability of dolutegravir/lamivudine in participants who switched from elvitegravir/cobicistat/emtricitabine/TAF were consistent with the overall switch population. Clinical Trials Registration NCT03446573.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofae227/57390033/ofae227.pdf

Reference19 articles.

1. 2-drug regimens in HIV treatment: pharmacological considerations;Back;Germs,2017

2. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel;Gandhi;JAMA,2023

3. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy–naive adults with HIV-1 infection;Cahn;AIDS,2022

4. Efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial;Osiyemi;Clin Infect Dis,2022

5. Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial;Llibre;Clin Infect Dis,2023